Differentiated exophytic vulvar intraepithelial lesion: Clinicopathologic and molecular analysis documenting its relationship with verrucous carcinoma of the vulva.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
31
03
2020
accepted:
07
05
2020
revised:
06
05
2020
pubmed:
20
5
2020
medline:
3
8
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Verruciform proliferations of the vulva unrelated to HPV infection are rare. The term differentiated exophytic vulvar intraepithelial lesion (DEVIL) was recently proposed for these lesions, which harbor recurrent PIK3CA mutations. It is still unclear whether DEVIL is related to verrucous carcinoma, a neoplasm characterized by persistence and local recurrence but nil risk of distant spread. Specimens identified using the words "verruciform" and "verrucous" were reviewed. Diagnosis of DEVIL required verruciform acanthosis, hyper and/or parakeratosis, hypogranulosis, cytoplasmic pallor, and bland nuclei. Verrucous carcinoma required, in addition, discontinuous, bulbous, puzzle-like nests in the stroma. A targeted next-generation sequencing using a custom 11-gene panel was performed. Eighteen specimens corresponding to ten patients with DEVIL and/or verrucous carcinoma were included. Median age at presentation was 66 years for DEVIL and 70 years for verrucous carcinoma. A similar spectrum of prevalent mutations was found in both lesions involving HRAS, PIK3CA, and BRAF. DEVIL preceded verrucous carcinoma and/or was diagnosed concurrently or in subsequent follow-up in five patients. In four of these, the same mutation was identified in DEVIL and synchronous or metachronous carcinoma. All cases showed wild-type 53 staining and lacked pathogenic TP53 mutations. DEVIL is a rare form of squamous proliferation characterized by prevalent PIK3CA and HRAS mutations. Its temporal relationship with verrucous carcinoma and their shared mutational profile in some patients suggest that DEVIL is a precursor of verrucous carcinoma. Moreover, given their morphologic and molecular overlap and the nil risk of verrucous carcinoma for distant spread, it is conceivable that DEVIL and verrucous carcinoma represent a spectrum of the same entity.
Identifiants
pubmed: 32427961
doi: 10.1038/s41379-020-0573-5
pii: S0893-3952(22)00470-7
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2011-2018Références
Kosary CL. Cancer of the vulva. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, patient and tumor characteristics. Bethesda MD: National Cancer Institute, SEER Program, National Institute of Health, Pub. No. 07-6215; 2007. p. 147–54.
Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinomas of the vulva. distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993;17:133–45.
doi: 10.1097/00000478-199302000-00005
Hording U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol. 1994;52:241–6.
doi: 10.1006/gyno.1994.1039
Bigby SM, Eva LJ, Jones RW. Spindle cell carcinoma of the vulva: a series of 4 cases and review of the literature. Int J Gynecol Pathol. 2014;33:203–12.
doi: 10.1097/PGP.0b013e31828bb49d
Singh N, Gilks CB. Vulval squamous cell carcinoma and its precursors. Histopathology. 2020;76:128–38.
doi: 10.1111/his.13989
McAlpine JN, Leung SCY, Cheng A, Miller D, Talhouk A, Gilks CB, et al. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Histopathology. 2017;71:238–46.
doi: 10.1111/his.13205
Leibowitch M, Neill S, Pelisse M, Moyal-Baracco M. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women. Br J Obstet Gynaecol. 1990;97:1135–9.
doi: 10.1111/j.1471-0528.1990.tb02502.x
Allo G, Yap ML, Cuartero J, Milosevic M, Ferguson S, Mackay H, et al. HPV-independent vulvar squamous cell carcinoma is associated with significantly worse prognosis compared with HPV-associated tumors. Int J Gynecol Pathol. 2019. https://doi.org/10.1097/PGP.0000000000000620 .
doi: 10.1097/PGP.0000000000000620
Nascimento AF, Granter SR, Cviko A, Yuan L, Hecht JL, Crum CP. Vulvar acanthosis with altered differentiation: A precursor to verrucous carcinoma? Am J Surg Pathol. 2004;28:638–43.
doi: 10.1097/00000478-200405000-00012
Watkins JC, Howitt BE, Horowitz NS, Ritterhouse LL, Dong F, MacConaill LE, et al. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017;30:448–58.
doi: 10.1038/modpathol.2016.187
Liu G, Li Q, Shang X, Qi Z, Han C, Wang Y, et al. Verrucous carcinoma of the vulva: A 20 year retrospective study and literature review. J Low Genit Trac Dis. 2016;20:114–8.
doi: 10.1097/LGT.0000000000000164
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon, France: IARC WHO Classification of Tumours, No 6; 2014. p. 234.
Tessier-Cloutier B, Kortekaas KE, Thompson E, Pors J, Chen J, Ho J, et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020. https://doi.org/10.1038/s41379-020-0524-1 .
doi: 10.1038/s41379-020-0524-1
pubmed: 32792599
Pors J, Tessier-Cloutier B, Ho J, Thompson E, Wong R, Trevisan G, et al. Verrucous carcinomas of the vulva: targeted next generation sequencing (NGS) and p53 immunohistochemistry (IHC) reveals p53 aberrations in 50% of cases. Mod Pathol. 2019;32 S2:1102A.
Kondi-Paphitis A, Deligeorgi-Politi H, Liapis A, Plemenou-Frangou M. Human papilloma virus in verrucus carcinoma of the vulva: an immunopathological study of three cases. Eur J Gynaecol Oncol. 1998;19:319–20.
pubmed: 9641242
Mehta V, Durga L, Balachandran C, Rao L. Verrucous growth on the vulva. Indian J Sex Transm Dis AIDS. 2009;30:125–6.
doi: 10.4103/0253-7184.62776
Robertson DI, Maung R, Duggan MA. Verrucous carcinoma of the genital tract: is it a distinct entity? Can J Surg. 1993;36:147–51.
pubmed: 8472225
Trietsch MD, Spaans VM, ter Haar NT, Osse EM, Peters AA, Gaarenstroom KN, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol. 2014;135:149–55.
doi: 10.1016/j.ygyno.2014.07.094
Nooij LS, Ter Haar NT, Ruano D, Rakislova N, van Wezel T, Smit VTHBM, et al. Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance. Clin Cancer Res. 2017;23:6781–9.
doi: 10.1158/1078-0432.CCR-17-1302
Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ. Induction of cyclin D1 overexpression by activated ras. Oncogene. 1994;9:3627–33.
pubmed: 7970723
Kiaris H, Spandidos D. Analysis of h-ras, k-ras and N-ras genes for expression, mutation and amplification in laryngeal tumors. Int J Oncol. 1995;7:75–80.
pubmed: 21552809
Al-Bannai R, Miller D, Sadownik L, Gilks CB. Vulvar acanthosis with altered differentiation (VAAD): report of a case with progression to poorly differentiated carcinoma over a 5-yr period. Int J Gynecol Pathol. 2015;34:385–9.
doi: 10.1097/PGP.0000000000000182